Skip to main content

Corporate insider profile

Keith A. Goldan Insider Trades

Keith A. Goldan has reported no open-market purchases on SEC Form 4 and is a net seller of $22,351 across 1 company. The most recent open-market transaction was reported on Jun 1, 2026. Source: SEC Form 4 filings.

Latest reported as Chief Financial Officer of Syndax Pharmaceuticals Inc (SNDX).

SEC-reported filing activity is provided for research purposes and is not investment advice.

Purchase filings
0
Reported companies
1
Net open-market value
-$22,351.23
Latest transaction
Jun 1, 2026

Affiliated corporations

Reported company relationships

Transaction history

Open-market Transactions

Open-market insider purchase and sale transactions
DateCompanyRoleTypeSharesPriceTotal value
Jun 1, 2026Syndax Pharmaceuticals Inc (SNDX)Chief Financial OfficerSale1,177$18.99$22,351

Common questions

Keith A. Goldan insider trading FAQ

Is Keith A. Goldan buying or selling stock?
Across all SEC Form 4 open-market filings on record, Keith A. Goldan is a net seller of $22,351, with no open-market purchases reported. The latest transaction was reported on Jun 1, 2026.
Which companies does Keith A. Goldan report insider trades for?
Keith A. Goldan has reported open-market trades in Syndax Pharmaceuticals Inc (SNDX). The latest SEC-reported relationship is Chief Financial Officer of Syndax Pharmaceuticals Inc (SNDX).
Where does Keith A. Goldan's insider trading data come from?
Watch Insiders reads the SEC Form 4 filings submitted to EDGAR under reporting owner CIK 1495411, and refreshes this page daily.